KALA BIO (KALA)

The company’s lead programme is KPI-012, a biologic candidate derived from human mesenchymal stem cell secretome. Rather than using live stem cells, the therapy is designed to deliver a broad mixture of human-derived biofactors, including growth factors, protease inhibitors, matrix proteins and neurotrophic factors. KALA BIO is developing KPI-012 to support corneal healing in severe ocular surface diseases where conventional approaches may be insufficient.

A key target indication for KPI-012 is persistent corneal epithelial defect, a rare and potentially vision-threatening disorder in which the cornea fails to heal after injury, surgery, infection or underlying disease. The company’s platform is also being explored for retinal degenerative conditions, including retinitis pigmentosa and Stargardt disease, where neuroprotective and regenerative mechanisms may be relevant.

KALA BIO operates in a specialised segment of ophthalmology that combines rare disease drug development with biologic and regenerative-medicine approaches. Its value proposition depends on clinical execution, regulatory progress and the ability to demonstrate that its secretome-based technology can improve outcomes in hard-to-treat eye disorders. As a development-stage biopharmaceutical company, it does not have the diversified revenue base of a commercial drugmaker and is closely tied to the success of its pipeline.